Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer.

PURPOSE Brain metastasis is usually a fatal event in patients with stage IV breast cancer. We hypothesized that its occurrence can be predicted if a clinical nomogram can be developed, thus allowing for selection of enriched patient populations for prevention trials. PATIENTS AND METHODS Electronic medical records of patients with metastatic breast cancer were retrospectively reviewed for the period between January 2000 and February 2007 under a study approved by the institutional review board. A multivariate logistic regression analysis of selected prognostic features was done. A nomogram to predict brain metastasis was constructed and validated in a cohort of 128 patients with brain metastasis treated at the Cross Cancer Institute (Edmonton, Alberta, Canada). Results Of 2,136 patients with breast cancer, 362 developed subsequent brain metastasis. Age, grade, negative status of estrogen receptor and human epidermal growth factor receptor 2, number of metastatic sites (one v > one), and short disease-free survival were significantly and independently associated with subsequent brain metastasis. The nomogram showed an area under the receiver operating characteristic curve (AUC) of 0.68 (95% CI, 0.66 to 0.69) in the training set. The validation set showed a good discrimination with an AUC of 0.74 (95% CI, 0.70 to 0.79). The nomogram was well calibrated, with no significant difference between the predicted and the observed probabilities. CONCLUSION We have developed a robust tool that is able to predict subsequent brain metastasis in patients with breast cancer with nonbrain metastatic disease. Selection of an enriched patient population at high risk for brain metastasis will facilitate the design of trials aiming at its prevention.

[1]  J. Mackey,et al.  Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  G. Hortobagyi,et al.  The natural history of breast cancer patients with brain metastases , 1979, Cancer.

[3]  R. Gelber,et al.  Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  M. Terris,et al.  Do nomograms predict aggressive recurrence after radical prostatectomy more accurately than biochemical recurrence alone? , 2009, BJU international.

[5]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[6]  Maria Werner-Wasik,et al.  Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial , 2004, The Lancet.

[7]  J. Goodwin,et al.  Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  E. Darai,et al.  Comparison of models to predict nonsentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: a prospective multicenter study. , 2009, Journal of Clinical Oncology.

[9]  A. Howell,et al.  Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer , 2004, British Journal of Cancer.

[10]  Raymond R Tubbs,et al.  Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR , 2006, The American journal of surgical pathology.

[11]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[12]  R A Patchell,et al.  Brain metastases. , 1991, Neurologic clinics.

[13]  E. Winer,et al.  Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma , 2003, Cancer.

[14]  L. Collette,et al.  Prophylactic cranial irradiation in extensive small-cell lung cancer. , 2007, The New England journal of medicine.

[15]  C. Swanton,et al.  Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab , 2006, Acta oncologica.

[16]  V. Budach,et al.  Prophylactic cranial irradiation in locally advanced non-small-cell lung cancer after multimodality treatment: long-term follow-up and investigations of late neuropsychologic effects. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  U. Capitanio,et al.  Can nomograms be superior to other prediction tools? , 2009, BJU international.

[18]  K. Altundağ.  Primary breast cancer phenotypes associated with propensity for central nervous system metastases , 2006, Cancer.

[19]  Yoshiaki Tsukada,et al.  Central nervous system metastasis from breast carcinoma autopsy study , 1983, Cancer.

[20]  M. Malkin,et al.  The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma , 2004, Cancer.

[21]  N. Wigler,et al.  Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment. , 2004, European journal of cancer.

[22]  K. Aldape,et al.  Defining prognosis for women with breast cancer and CNS metastases by HER2 status. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  Liao Ning,et al.  Nomograms to Predict Pathologic Complete Response and Metastasis-Free Survival after Preoperative Chemotherapy for Breast Cancer , 2007 .

[24]  M. Suntharalingam,et al.  Evaluation of the use of prophylactic cranial irradiation in small cell lung cancer , 2009, Cancer.

[25]  W. Gerald,et al.  Genes that mediate breast cancer metastasis to the brain , 2009, Nature.

[26]  B. O'neill,et al.  Brain Metastases , 2004, The neurologist.

[27]  J. Engel,et al.  Determinants and prognoses of locoregional and distant progression in breast cancer. , 2003, International journal of radiation oncology, biology, physics.

[28]  G. Hortobagyi,et al.  Trastuzumab treatment and the risk of central nervous system (CNS) metastases , 2007 .

[29]  E. Winer,et al.  CNS metastases in breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  David Cameron,et al.  2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial , 2007, The Lancet.

[31]  F. Heitz,et al.  Cerebral metastases (CM) in breast cancer (BC) with focus on triple-negative tumors , 2008 .

[32]  M. Milella,et al.  Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials , 2008, Breast Cancer Research and Treatment.

[33]  E. Lower,et al.  Increased rate of brain metastasis with trastuzumab therapy not associated with impaired survival. , 2003, Clinical breast cancer.